Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel

    Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel

Oramed to Present on Tuesday, June 11, 2013, at 3:10 p.m. (IDT)

PR Newswire

JERUSALEM, June 10, 2013

JERUSALEM, June 10, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a clinical-stage developer of
oral delivery systems, announced today that it has been invited to present at
the 12^th National Life Science & Technology Week IATI-BioMed Conference
taking place from June 10-12, 2013, in Tel Aviv, Israel. Josh Hexter, Oramed's
Chief Operating Officer and Vice President of Business Development, will
present on Tuesday, June 11^th at 3:10 PM.

IATI-BioMed 2013 follows the success of previous annual conferences where the
Israeli Life Science Industry (ILSI) hosted 6,000 industry players, engineers
and scientists with approximately 1,000 participants from over 40 countries,
and in excess of 3,500 one-on-one meetings.

About IATI-BioMed

The IATI-BioMed conference, formerly known as the ILSI-BioMed Conference, is
Israel's premier life science conference showcasing the country's most
advanced companies and technologies. Building on the great reputation
established in previous years, IATI-BioMed offers attendees and presenters a
winning mix of industry keynote speakers, exciting and innovative company
presentations, and three days of exhibition and networking opportunities. In
addition, the Academic Institution's Technology Transfer offices and
scientists from Israel's universities and healthcare institutions are present
throughout the event.

For more information on the IATI-BioMed conference, the content of which is
not part of this press release, please visit:
http://www2.kenes.com/biomed/Pages/Home.aspx

About Oramed

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's technology is based on over 30 years of research
by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its proprietary
flagship product, an orally ingestible insulin capsule (ORMD-0801) currently
initiating Phase 2 clinical trials under an Investigational New Drug
application with the U.S. Food and Drug Administration, and with its oral
exenatide capsule (ORMD-0901; a GLP-1 analog), with trials on healthy
volunteers (Phase 1b) and diabetic patients (Phase 2a) underway. The company's
corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release,
please visithttp://www.oramed.com

Forward-looking statements: This press release contains forward-looking
statements. For example, we are using forward-looking statements when we
discuss revolutionizing the treatment of diabetes with our products, or when
we discuss our clinical trials. These forward-looking statements are based on
the current expectations of the management of Oramed only, and are subject to
a number of factors and uncertainties that could cause actual results to
differ materially from those described in the forward-looking statements,
including the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs; difficulties
or delays in obtaining regulatory approval or patent protection for our
product candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to conduct
our research, development and commercialization activities. In addition, the
following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: changes in
technology and market requirements; delays or obstacles in launching our
clinical trials; changes in legislation; inability to timely develop and
introduce new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our methods by
the scientific community; inability to retain or attract key employees whose
knowledge is essential to the development of our products; unforeseen
scientific difficulties that may develop with our process; greater cost of
final product than anticipated; loss of market share and pressure on pricing
resulting from competition; laboratory results that do not translate to
equally good results in real settings; our patents may not be sufficient; and
final that products may harm recipients, all of which could cause the actual
results or performance of Oramed to differ materially from those contemplated
in such forward-looking statements. Except as otherwise required by law,
Oramed undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Office:+972-2-566-0001
Mobile: +972-54-792-4438
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.
 
Press spacebar to pause and continue. Press esc to stop.